AstraZeneca (STU:ZEGA) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ZEGA AstraZeneca PLC STU:ZEGA
88 GF Score
Price €78.00
GF Value €90.78
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (STU:ZEGA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.24 9.33 8.20 7.46 8.93

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.84 7.41 8.93 9.28 8.63

STU:ZEGA vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.


STU:ZEGA
88GF Score
AstraZeneca PLC STU:ZEGA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.08/142.3000*142.3000
=14.080

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201609 4.604 101.500 6.455
201612 5.565 102.200 7.749
201703 4.796 102.700 6.645
201706 4.800 103.500 6.599
201709 4.548 104.300 6.205
201712 4.992 105.000 6.765
201803 4.135 105.100 5.599
201806 4.273 105.900 5.742
201809 4.037 106.600 5.389
201812 4.325 107.100 5.746
201903 3.536 107.000 4.703
201906 4.570 107.900 6.027
201909 4.210 108.400 5.527
201912 4.502 108.500 5.904
202003 3.717 108.600 4.870
202006 4.140 108.800 5.415
202009 3.945 109.200 5.141
202012 4.891 109.400 6.362
202103 4.617 109.700 5.989
202106 4.956 111.400 6.331
202109 10.904 112.400 13.805
202112 11.215 114.700 13.914
202203 10.648 116.500 13.006
202206 10.969 120.500 12.953
202209 11.451 122.300 13.324
202212 11.280 125.300 12.810
202303 10.784 126.800 12.102
202306 11.134 129.400 12.244
202309 11.244 130.100 12.298
202312 11.578 130.500 12.625
202403 11.111 131.600 12.014
202406 11.839 133.000 12.667
202409 11.833 133.500 12.613
202412 12.564 135.100 13.234
202503 12.244 136.100 12.802
202506 12.505 138.400 12.857
202509 12.610 138.900 12.919
202512 13.405 139.900 13.635
202603 13.205 140.800 13.346
202606 14.080 142.300 14.080

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (STU:ZEGA) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €78.00 is trading 14.1% below its estimated GF Value™ of €90.78.

Key valuation signals for STU:ZEGA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €90.78 vs. price of €78.00 (14.1% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for STU:ZEGA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€78.00
Price
€90.78
GF Value